Diamedica Therapeutics Inc (DMAC) Stock Price, Quote & News

Company Profile

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company also develops DM300, which is a recombinant human...

Industry: Biotechnology

Sector: Healthcare

Phone: 763 496 5454

Website: www.diamedica.com

Address:

301 Carlson Parkway, Suite 210, Minneapolis, United States

Tjcmd Jul. 22 at 9:42 PM

$DMAC anyone know what’s up with their CMO?

0 · Reply

MadMaverick Jul. 21 at 4:54 PM

$DMAC is above $5. Congrats on that trade. SOLID GAINS!! 💰

0 · Reply

DonCorleone77 Jul. 21 at 1:22 PM

$DMAC DiaMedica Therapeutics to sell 8.606M shares at $3.50 in private placement

0 · Reply

kellymone2 Jul. 21 at 1:03 PM

$DMAC Hi. Which is your target here?

0 · Reply

justiceforb_85 Jul. 20 at 12:07 AM

$DMAC preliminary data in pre-eclampsia is promising but wondering why the company said the US studies would be performed next year?

1 · Reply

anachartanalyst Jul. 18 at 4:06 PM

$DMAC https://anachart.com/wp-content/uploads/ana_temp/1752854539_soc-img.jpg

0 · Reply

judgeyoung2 Jul. 18 at 2:36 PM

$BHVN $DMAC $GRI $LLY $MTSR still waiting

0 · Reply

JarvisFlow Jul. 18 at 11:00 AM

HC Wainwright & Co. has updated their rating for DiaMedica Therapeutics ( $DMAC ) to Buy with a price target of 12.

0 · Reply

CompoundFCF Jul. 17 at 8:47 PM

Absolutely no reason why $DMAC should not have been wildly higher on the day. Met all three endpoints. 1 - drop in BP ✔️, 2 - did not cross placental barrier ✔️, 3 - dilation of intrauterine artery ✔️. Number 3 is just gravy. What am I missing?

1 · Reply

MedCred Jul. 17 at 7:44 PM

$DMAC Great data ! 1. Big drop in BP 2. Doesn’t cross placenta. This is huge for safety of child and the hang up with most blood pressure Medications available to no pregnant people 3. Dilates placental arteries. From the perspective of millions of pregnant women all over the world this is big news. Preeclampsia leads to so many deaths and premature births and perinatal problems around the world. This is huge ! https://finance.yahoo.com/news/diamedica-therapeutics-reports-positive-interim-120000889.html

1 · Reply

DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline

Jul 17, 2025, 8:00 AM EDT - 5 days ago

DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer

Jun 24, 2025, 8:30 AM EDT - 4 weeks ago

DiaMedica Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes

May 22, 2025, 8:30 AM EDT - 2 months ago

DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025

May 19, 2025, 9:00 AM EDT - 2 months ago

DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia

May 14, 2025, 4:30 PM EDT - 2 months ago

DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference – ESOC 2025

May 14, 2025, 11:05 AM EDT - 2 months ago

DiaMedica Therapeutics Inc. (DMAC) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:30 PM EDT - 2 months ago

DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights

May 8, 2025, 4:00 PM EDT - 2 months ago

DiaMedica Therapeutics to Participate in Upcoming Investor Conferences in May

May 7, 2025, 8:30 AM EDT - 2 months ago

DiaMedica Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update May 14, 2025

Mar 18, 2025, 10:27 AM EDT - 4 months ago

DiaMedica Therapeutics Inc. (DMAC) Q4 2024 Earnings Call Transcript

Mar 17, 2025, 4:30 PM EDT - 4 months ago

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results

Mar 11, 2025, 8:23 AM EDT - 4 months ago

DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025

Feb 24, 2025, 8:30 AM EST - 5 months ago

DiaMedica Therapeutics Appoints Daniel J. O'Connor to the Board of Directors

Feb 20, 2025, 8:15 AM EST - 5 months ago

DiaMedica Therapeutics Announces Publication of DM199's Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke

Feb 10, 2025, 4:15 PM EST - 5 months ago

DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Dec 3, 2024, 8:25 AM EST - 8 months ago

DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia

Nov 14, 2024, 12:49 PM EST - 8 months ago

DiaMedica Therapeutics Inc. (DMAC) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 4:20 PM EST - 8 months ago

DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results

Nov 13, 2024, 4:05 PM EST - 8 months ago

DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia

Nov 12, 2024, 8:23 AM EST - 9 months ago

DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference

Nov 6, 2024, 8:32 AM EST - 9 months ago

DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024

Oct 9, 2024, 8:27 AM EDT - 10 months ago

DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia

Sep 4, 2024, 4:15 PM EDT - 11 months ago

DiaMedica Therapeutics Upcoming Conference Participation

Aug 7, 2024, 4:15 PM EDT - 1 year ago

DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results

Aug 1, 2024, 8:20 AM EDT - 1 year ago

DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024

Jul 11, 2024, 2:48 PM EDT - 1 year ago

DiaMedica: Early 2025 Interim Futility Analysis Could Be A Major Inflection Point

Jul 11, 2024, 8:00 AM EDT - 1 year ago

DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia

Jul 1, 2024, 8:00 AM EDT - 1 year ago

DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement

Jun 26, 2024, 8:15 AM EDT - 1 year ago

DiaMedica Therapeutics Announces $11.8 Million Private Placement

Jun 26, 2024, 8:00 AM EDT - 1 year ago

DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia

May 11, 2024, 4:49 PM EDT - 1 year ago

DiaMedica Therapeutics Inc. (DMAC) Q1 2024 Earnings Call Transcript

May 8, 2024, 4:30 PM EDT - 1 year ago

DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results

May 2, 2024, 8:55 AM EDT - 1 year ago

DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024

Apr 17, 2024, 4:08 PM EDT - 1 year ago

DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke

Mar 20, 2024, 4:14 PM EDT - 1 year ago

DiaMedica Therapeutics Inc. (DMAC) Q4 2023 Earnings Call Transcript

Mar 19, 2024, 4:15 PM EDT - 1 year ago

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results

Jan 29, 2024, 4:13 PM EST - 1 year ago

DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference

Jan 22, 2024, 8:23 AM EST - 1 year ago

DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer

Nov 14, 2023, 12:10 PM EST - 1 year ago

DiaMedica Therapeutics Inc. (DMAC) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 4:28 PM EST - 1 year ago

DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results

Nov 9, 2023, 8:25 AM EST - 1 year ago

DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023

Nov 6, 2023, 8:23 AM EST - 1 year ago

DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023

Sep 12, 2023, 8:13 AM EDT - 2 years ago

DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer

Sep 6, 2023, 8:35 AM EDT - 2 years ago

DiaMedica Therapeutics to Participate at Lake Street's 7th Annual Best Ideas Growth Conference

Aug 15, 2023, 3:43 PM EDT - 2 years ago

DiaMedica Therapeutics Inc. (DMAC) Q2 2023 Earnings Call Transcript

Aug 14, 2023, 4:13 PM EDT - 2 years ago

DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results

Aug 8, 2023, 8:32 AM EDT - 2 years ago

DiaMedica Therapeutics to Report Second Quarter 2023 Financial Results and Provide a Business Update August 15, 2023

Jul 18, 2023, 8:30 AM EDT - 2 years ago

DiaMedica Therapeutics to Attend the American Academy of Neurology Summer Conference

Jun 26, 2023, 8:30 AM EDT - 2 years ago

DiaMedica Therapeutics Announces Closing of $37.5 Million Private Placement

Tjcmd Jul. 22 at 9:42 PM

$DMAC anyone know what’s up with their CMO?

0 · Reply

MadMaverick Jul. 21 at 4:54 PM

$DMAC is above $5. Congrats on that trade. SOLID GAINS!! 💰

0 · Reply

DonCorleone77 Jul. 21 at 1:22 PM

$DMAC DiaMedica Therapeutics to sell 8.606M shares at $3.50 in private placement

0 · Reply

kellymone2 Jul. 21 at 1:03 PM

$DMAC Hi. Which is your target here?

0 · Reply

justiceforb_85 Jul. 20 at 12:07 AM

$DMAC preliminary data in pre-eclampsia is promising but wondering why the company said the US studies would be performed next year?

1 · Reply

anachartanalyst Jul. 18 at 4:06 PM

$DMAC https://anachart.com/wp-content/uploads/ana_temp/1752854539_soc-img.jpg

0 · Reply

judgeyoung2 Jul. 18 at 2:36 PM

$BHVN $DMAC $GRI $LLY $MTSR still waiting

0 · Reply

JarvisFlow Jul. 18 at 11:00 AM

HC Wainwright & Co. has updated their rating for DiaMedica Therapeutics ( $DMAC ) to Buy with a price target of 12.

0 · Reply

CompoundFCF Jul. 17 at 8:47 PM

1 · Reply

MedCred Jul. 17 at 7:44 PM

1 · Reply

MadMaverick Jul. 17 at 6:23 PM

$DMAC update from initial spotlight! +7% Again, on News 20%+ Gain from original alert 👏 $NDRA $PROK $BTCS

0 · Reply

Tjcmd Jul. 17 at 5:23 PM

$DMAC nice!

0 · Reply

rml360 Jul. 17 at 2:48 PM

$DMAC fools selling at 3.65

0 · Reply

Stmkr Jul. 17 at 1:30 PM

$DMAC needs a good cash raise. I hope management can do this on decent terms given the potential of their asset in two large markets

0 · Reply

rml360 Jul. 17 at 1:21 PM

$DMAC lets push this over 4 to the open

0 · Reply

rml360 Jul. 17 at 1:08 PM

$DMAC who the hell is selling this low

0 · Reply

rml360 Jul. 17 at 12:49 PM

$DMAC this should be green at a minimum, buying more

0 · Reply

Reneejordan001 Jul. 17 at 12:34 PM

$DMAC This is only interim data results so that is why it's not pumping IMO

0 · Reply

Stmkr Jul. 17 at 12:33 PM

$DMAC Market underreacting to the news? Fear of cash raise? Am I missing sth? Preeclampsia indication seems pretty derisked

1 · Reply

DARKP00L Jul. 17 at 12:22 PM

$DMAC 08:20 on Jul. 17 2025 DiaMedica Therapeutics Announces Interim Results From Part 1a Of Phase 2 Study Of DM199 For Treatment Of Preeclampsia #tradeideas

0 · Reply

Thestocktraderhubzee Jul. 17 at 12:22 PM

$DMAC DiaMedica Therapeutics Announces Interim Results From Part 1a Of Phase 2 Study Of DM199 For Treatment Of Preeclampsia

0 · Reply

rml360 Jul. 17 at 12:21 PM

$DMAC thought it would be at least up a buck on these good results

0 · Reply

Market Cap	179.25M
Revenue (ttm)	0.00
Net Income (ttm)	-24.44M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	314,900
Avg Vol	250,842
Day's Range	N/A - N/A
Shares Out	42.88M
Stochastic %K	66%
Beta	1.17
Analysts	Strong Sell
Price Target	$10.67